7:30 a.m.-5 p.m.
Registration/Course Enrollment Open
8 a.m.-11 a.m.
IS7. Diagnosis and Treatment Issues in Child and Adolescent Bipolar Disorders Supported by Abbott Laboratories
A. Diagnosis and Course of Bipolar Disorder in Children and Adolescents Karen D. Wagner, M.D.
B. Genetic and Environmental Effects of Bipolar Disorder on Families and Offspring Kiki D. Chang, M.D.
C. Pharmacologic Treatment of Children and Adolescents With Bipolar Disorders Robert A. Kowatch, M.D.
D. Novel and Maintenance Treatment Approaches in Pediatric Bipolarity Robert L. Findling, M.D.
E. Diagnostic and Treatment Implications of Psychiatric Comorbidity in Juvenile BPD Timothy E. Wilens, M.D.
IS8. Late-Life Depression: Old Myths and New Data Supported by Forest Laboratories Inc.
A. Late-Life Depression: Neuroanatomy and Medical Comorbidity Anand Kumar, M.D.
B. Depression: Pseudodementia and Executive Dysfunction George S. Alexopoulos, M.D.
C. How Long Should Antidepressant Trials Be in Geriatric Depression? Harold Sackheim, Ph.D.
D. Treatment of Depression in the Elderly Steven P. Roose, M.D.
E. Interpersonal Therapy in Late-Life Depression: Who Benefits? Charles F. Reynolds III, M.D.
IS9. Depressive Subtypes: The Multiple Faces of Depression Supported by Organon Inc.
A. Atypical Depression: An Often Under-Recognized Condition Jonathan W. Stewart, M.D.
B. Treatment Challenges in Anxious Depression Maurizio Fava, M.D.
C. Melancholic Depression: Are Dual-Action Antidepressants Superior to Selective Agents? J. Craig Nelson, M.D.
D. Vascular Depression Ranga K. Krishnan, M.D.
E. Practical Approach to Psychotic Depression Linda L. Carpenter, M.D.
IS10. Recovery From Depression: New Perspectives to Improve Outcomes Supported by Wyeth-Ayerst Laboratories
A. Recovery From Depression: Conceptual Underpinnings Michael E. Thase, M.D.
B. Augmentation and Combination Strategies for the Newer Antidepressants Andrew A. Nierenberg, M.D.
C. Combining Psychotherapy and Medication for Depression John C. Markowitz, M.D.
D. Maximizing Efficacy in the Treatment of Chronic Depression Susan G. Kornstein, M.D.
IS11. Treating Psychotic Illness Across the Life Span: Are Drugs Enough? Supported by Eli Lilly and Company
A. Best Practices in Psychosocial Rehabilitation for Psychotic Illnesses Paul J. Barreira, M.D.
B. From Getting By to Getting Better Gerald A. Maguire, M.D.
C. Is the Cheapest Alternative the Most Economical? Sumer Verma, M.D.
D. Raising the Bar of Expectations Ralph Aquila, M.D.
E. Childhood Psychosis Jean A. Frazier, M.D.
F. Madness and the Rest of a Life Anne Alonso, Ph.D.
IS12. Advances in the Treatment of Psychosis: Minimizing the Burden of Disease Supported by Bristol-Myers Squibb Company
A. Where Have We Been? Where Are We Heading? Daniel R. Weinberger, M.D.
B. The Public Health Importance of Schizophrenia Norman Sartorius, M.D.
C. Redefining Outcomes in Schizophrenia: Improving Function While Reducing Symptoms Andrew J. Cutler, M.D.
D. A Personal Perspective: Living With a Person With Schizophrenia Martin S. Willick, M.D.
CME Courses 17-22
8 a.m.-4:30 p.m.
APA Resource Center Open
9 a.m.-4 p.m.
CME Courses 23-29
11 a.m.-4:30 p.m.
Publishers’ Bookfair Open
12:30 p.m.-1:30 p.m.
Business Meeting and Forum (Voting Members Only)
1 p.m.-5 p.m.
CME Courses 30-38
1:30 p.m.-4:30 p.m.
IS13. Recent Developments in the Science and Treatment of PTSD Supported by GlaxoSmithKline
A. Risk and Resilience Factors in PTSD Rachel Yehuda, Ph.D.
B. What Can Neuroimaging Teach Us About PTSD? Scott L. Rauch, M.D.
C. Medication Strategies in PTSD David V. Sheehan, M.D.
D. Treatment of PTSD With Exposure Therapy Barbara O. Rothbaum, Ph.D.
E. Using Assessment Tools in Clinical Practice: When, Why, and How? Kathryn M. Connor, M.D.
IS14. Customizing Care for Patients With Bipolar Disorder Supported by AstraZeneca Pharmaceuticals
A. Intervention for Refractory Patients Patricia Suppes, M.D.
B. Significance of Psychosis Charles L. Bowden, M.D.
C. Choosing Initial Mood Stabilizer After Acute Mania Guy M. Goodwin, M.D.
D. Selection of an Acute Treatment Strategy: Sequential Versus Stratified Approach Gary S. Sachs, M.D.
E. Dealing With Common Problems During Ongoing Treatment in Bipolar Disorder W. Gordon Frankle, M.D.
IS15. The Aging Brain and Vulnerability to Depression Supported by Organon Inc.
A. Age, Neurobiology, and Treatment Response Madhukar H. Trivedi, M.D.
B. The Impact on Cognition of Pharmacological Treatment for Late-Life Depression Ruth O’Hara, Ph.D.
C. Pharmacogenetics in Geriatric Depression Greer M. Murphy, M.D.
D. Treatment of the Depressed: Old-Old in Outpatient and Long-Term Care Settings Steven P. Roose, M.D.
IS16. Long-Term Management of Mood Disorders Supported by Cyberonics Inc.
A. Does Medication Change the Long-Term Course of Mood Disorders? Susan G. Kornstein, M.D.
B. Does Psychotherapy Change the Long-Term Course of Mood Disorders? Robin B. Jarrett, Ph.D.
C. Does ECT Alter the Long-Term Course of Mood Disorders? Harold Sackheim, Ph.D.
D. Vagus Nerve Stimulation for Depression: Methods and Mechanisms Mark S. George, M.D.
E. Does Vagus Stimulation Change the Long-Term Course of Mood Disorders? Lauren B. Marangell, M.D.
IS17. The Adherence Challenge: Chronic Issues and Emerging Solutions With Antipsychotic Therapy Supported by Janssen Pharmaceutica
A. Approaching the Adherence Challenge Stephen R. Marder, M.D.
B. Pharmacologic Options for Schizophrenia: Implications for Compliance John M. Kane, M.D.
C. Research Experience With Long-Acting Atypical Antipsychotic Medication Samuel J. Keith, M.D.
D. Views From the Nursing Perspective: Problems and Solutions Kathleen Jarboe, R.N.
E. Patient Compliance With Antipsychotic Therapy: Economic and Clinical Issues Raymond C. Love, Pharm.D.
IS18. Challenges and Opportunities in the Management of Psychotic Disorders Supported by Bristol-Myers Squibb Company
A. Defining the Prodromal Phase and Exploring Interventions: Evidence in Transition Patrick D. McGorry, Ph.D.
B. Management of Psychotic Disorders: First-Line Therapy for Acute Episodes Diana O. Perkins, M.D.
C. Outcomes in Schizophrenia: Where Are We Heading? Peter J. Weiden, M.D.
D. Enhancing Quality of Life: Role of Safety and Tolerability Joseph P. McEvoy, M.D.
E. Does an Antipsychotic’s Mechanism of Action Make a Difference in Clinical Management? Jeffrey A. Lieberman, M.D.
2:30 p.m.-4 p.m.
L1. Rethinking Risk Assessment: The MacArthur Study of Mental Disorder and Violence John Monahan, Ph.D.AAPL/APA’s Manfred S. Guttmacher Award Lecture
5 p.m.-6:30 p.m.
Opening Session and Presidential Address
7 p.m.-10 p.m.
IS19. Treatment of Anxiety Disorders: Where Are We, and Where Are We Going? Supported by Pfizer Inc.
A. Comorbidities and Issues to Consider in the Management of Anxiety Disorders Ronald C. Kessler, Ph.D.
B. Management of Depression in Anxiety Disorders Naomi M. Simon, M.D.
C. Managing the Disordered Sleep Associated With Anxiety and Mood Disorders John W. Winkelman, M.D.
D. GAD: Long-Term Treatment to Improve Outcome Mark H. Pollack, M.D.
E. Current and Future Treatments for Anxiety: Efficacy and Tolerability R. Bruce Lydiard, M.D.
IS20. Atypical Depression: Overview and New Developments Supported by Somerset Pharmaceuticals Inc.
A. The Biology of Atypical Depression Ranga K. Krishnan, M.D.
B. The Biology of PTSD and Atypical Depression: The Role of Early-Life Trauma Linda L. Carpenter, M.D.
C. Diagnostic Issues in Atypical Depression Alan F. Schatzberg, M.D.
D. Psychotherapy in the Treatment of Major Depression Barbara O. Rothbaum, Ph.D.
E. New Treatments for Atypical Depression Charles B. Nemeroff, M.D.
IS21. New Developments in the Treatment of Bipolar Disorder Supported by Abbott Laboratories
A. Advances in the Treatment of Mania Gary S. Sachs, M.D.
B. Update on the Treatment of Bipolar Depression Robert M.A. Hirschfeld, M.D.
C. Stabilizing the Course of Refractory Bipolar Illness: Meeting the Challenges of Rapid-Cycling and Mixed Mania Patricia Suppes, M.D.
D. Update on Psychosocial Treatments of Bipolar Disorder Michael W. Otto, Ph.D.
E. The Multiple Goals of Maintenance Treatment Charles L. Bowden, M.D.
IS22. Treatment of Mood and Anxiety Disorders in Women: What Is Evidence and What Is Art? Supported by Wyeth-Ayerst Laboratories
A. Treatment of Mood Disorders in Pregnancy and the Postpartum Period Lee S. Cohen, M.D.
B. Course and Treatment of Bipolar Illness During Pregnancy and the Postpartum Period Adele C. Viguera, M.D.
C. New Strategies in Managing PMDD Kimberly A. Yonkers, M.D.
D. Gender as a Factor M. Katherine Shear, M.D.
IS23. Primary Mood Stabilizers as the Cornerstone of Treatment for Bipolar Disorder Supported by Eli Lilly and Company
A. Practical Approaches to Recognizing and Managing Side Effects Paul E. Keck Jr., M.D.
B. Mania and Mood Stabilization: What’s New? Lauren B. Marangell, M.D.
C. Treating Depression and Suicidality Michael E. Thase, M.D.
D. Update on the Treatment of Rapid-Cycling Bipolar Disorder Joseph F. Goldberg, M.D.
E. Compliance and Optimizing Function Guy M. Goodwin, M.D.
F. The Doctor/Patient Relationship: How to Get Help for the One You Love Mary R. Worthen
IS24. Molecules of the Mind: The Science of Schizophrenia Supported by AstraZeneca Pharmaceuticals
A. The Neurobiology of Cognitive Dysfunction in Schizophrenia David A. Lewis, M.D.
B. Nicotinic Receptors and the Genetics of Schizophrenia and Bipolar Disorder Robert Freedman, M.D.
C. Glutamatergic Transmission in Schizophrenia Carol A. Tamminga, M.D.
D. White-Matter Abnormalities in Schizophrenia Kenneth L. Davis, M.D.
E. Molecular Biology and Genetics of Cortical Function in Schizophrenia Daniel R. Weinberger, M.D.
F. Neuroplasticity and Cellular Resilience in Mood Disorders Husseini K. Manji, M.D.
Session 1. Holocaust Memories
1. Our Children
Session 2. Psychiatry Goes to the Movies
2. Memento ▪
Download citation file:
Please confirm that your email address is correct, so you can successfully receive this alert.